Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/8/2009

>

                               PALATIN TECHNOLOGIES, INC.
                       Consolidated Statement of Operations Data
                                      (unaudited)


                                Year Ended June 30,     Quarter Ended June 30,
                                  2009          2008        2009         2008

    REVENUES               $11,351,774   $11,483,287  $4,227,070   $1,015,764

    OPERATING EXPENSES:
      Research and
       development          13,356,751    21,187,762   3,045,423    4,891,494
      General and
       administrative        5,296,859     6,928,295   1,415,171    1,460,066
        Total operating
         expenses           18,653,610    28,116,057   4,460,594    6,351,560

        Loss from
         operations         (7,301,836)  (16,632,770)   (233,524)  (5,335,796)

    OTHER INCOME (EXPENSE):
      Investment income        233,319     1,030,452      38,137      122,162
      Interest expense         (26,159)      (73,495)     (5,143)     (28,661)
      Gain on sale of
       property and equipment  550,968             -           -            -
        Total other income,
         net                   758,128       956,957      32,994       93,501

        Loss before income
         taxes              (6,543,708)  (15,675,813)   (200,530)  (5,242,295)
    Income tax benefit       1,741,476     1,291,444           -            -

    NET LOSS               $(4,802,232) $(14,384,369)  $(200,530) $(5,242,295)

    Basic and diluted net
     loss per common share      $(0.06)       $(0.17)     $(0.00)      $(0.06)

    Weighted average number
     of common shares
     outstanding used in
     computing basic and
     diluted net loss per
     common share           86,370,306    85,220,575  86,662,901   85,297,321

                              PALATIN TECHNOLOGIES, INC.
                            Consolidated Balan
'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the Netherlands ... His Majesty Willem-Alexander, King of the Netherlands, has announced ... POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant in ... will take part in the Grand Opening Ceremony to ... p.m. and tour the plant. POET-DSM is a joint ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2
... DIEGO, Sept. 2 Halozyme Therapeutics,Inc. (Nasdaq: ... and,commercializing products targeting the extracellular matrix, today,announced ... President,Research, Michael J. LaBarre, PhD, Vice President, ... Legal., "Halozyme is committed to attracting, ...
... licenses ... STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ... to end the OxyContin(R) (oxycodone HCl controlled-release) Tablets,patent infringement ... the Southern District of New York., According to ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... the Company is initiating a U.S.,Phase 2 ... in,combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal,Investigator is Dr. ...
Cached Biology Technology:Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... and Canadian research team surveying mercury contamination in fish ... Canada has identified five "hotspots" where concentrations of the ... The team focused on levels of the potent neurotoxin ... took into account contamination in other fish, birds, and ...
... of thousands of heart patients to have high-tech devices implanted ... expensive devices are designed to shock damaged hearts back into ... 300,000 Americans each year. , But a new study finds ... ICDs, a large number won't -- and a simple heart-rhythm ...
... from grain, but the U.S. Department of Energy (DOE) would ... alternatives, such as paper pulp, sawdust, straw and grain hulls. ... by analyzing the DNA of a bacterium that can break ... also found in forestry by-products (including paper) and waste feedstocks. ...
Cached Biology News:Hotspots of mercury contamination identified in eastern North America 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 3McBride shows DNA detective work with paper-eating bacteria that 'glide' 2McBride shows DNA detective work with paper-eating bacteria that 'glide' 3
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in ... required. Purity: ≥98% by TLC. Soluble in ... preparation of a 10 mM stock in DMSO is ... to H 2 O with rapid mixing (e.g. 10 ...
Monoclonal antibodies conjugated with rhodamine...
... Rhodopsin is a glycoprotein which is ... and reptiles. The rhodopsin protein is present ... Immunogen: Membrane preparation from ... This antibody specifically labels the axons andsynaptic ...
Biology Products: